A multicenter, randomized, double‐blind, placebo‐controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open‐label extension

Headache: The Journal of Head and Face Pain Pub Date : 2022-10-01 DOI:10.1111/head.14391

M. Yonker, J. McVige, L. Zeitlin, H. Visser

引用次数: 2

Abstract

To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in patients aged 6 to 11 years.

查看原文本刊更多论文

一项多中心、随机、双盲、安慰剂对照的交叉试验，旨在评估唑米曲坦鼻喷雾剂治疗6 - 11岁急性偏头痛患者的疗效和安全性，并进行开放标签扩展

评价唑米曲坦鼻喷雾剂(ZNS)治疗6 ~ 11岁急性偏头痛患者的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

自引率

0.00%

发文量